Alterity Therapeutics to Present at the MST Access Australian Micro & Small Caps Conference
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to creating
Read More
We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.
First-in-class therapies to treat neurodegenerative disease
Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
News
Quarterly Cash Flow Report
Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson’s disease research evaluation Strengthening profile at investm
Read MoreATH434 protects brain cells and improves motor function
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced an oral presentation of expanded animal
Read MoreReceive news from Alterity Therapeutics
